Isofenal (Ketoprofen)

Ketoprofen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, the drug diminishes inflammation, pain signaling, and fever at the site of tissue injury.

The appropriate dose of Isofenal is determined by the prescribing clinician based on the specific indication, severity of symptoms, patient weight, renal and hepatic function, and other individual factors. Healthcare professionals adjust the regimen to achieve optimal therapeutic effect while minimizing risk.

Safety data for ketoprofen during pregnancy and lactation are limited. The product should be avoided in the third trimester and used only if the potential benefit outweighs the possible risk. Breastfeeding mothers should consult their physician, as ketoprofen may be excreted in breast milk.

To request Isofenal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Ketoprofen has a potency comparable to ibuprofen and naproxen but offers a relatively rapid onset of analgesia when given intramuscularly. Its dual COX‑1/COX‑2 inhibition provides strong anti‑inflammatory effects, yet it shares the typical NSAID risk profile, including gastrointestinal and renal considerations.

Isofenal must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use, and discard any vial that shows signs of contamination or temperature abuse.

Isofenal is supplied as a sterile solution for intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and the dosage instructions provided by the prescriber.

The most serious adverse events include gastrointestinal bleeding or ulceration, severe renal impairment, hepatic dysfunction, life‑threatening skin reactions such as Stevens‑Johnson syndrome, anaphylactic shock, and increased risk of cardiovascular thrombotic events like myocardial infarction or stroke.

Isofenal is contraindicated in patients with known hypersensitivity to ketoprofen or other NSAIDs, active peptic ulcer disease, severe renal or hepatic impairment, uncontrolled hypertension, and in the third trimester of pregnancy. Caution is also advised for individuals with a history of cardiovascular disease or bleeding disorders.